Company / SG&A Expense
ENANTA PHARMACEUTICALS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$52.9M
FY2025
5-year range
$26.2M / $52.9M
FY2021-FY2025
Trend
+16.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 9 consecutive years, from $10M in FY2016 to $53M in FY2025.
Based on SEC 10-K filings.
$53M in FY2025 with a 5-year CAGR of +17.7%.
Increased from $33M to $53M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +24.6%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +17.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 16.3% year-over-year.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.9M | +16.3% |
| FY2024 | $45.5M | +39.8% |
| FY2023 | $32.5M | +18.9% |
| FY2022 | $27.4M | +4.2% |
| FY2021 | $26.2M | +12.0% |
| FY2020 | $23.4M | +13.0% |
| FY2019 | $20.7M | +22.3% |
| FY2018 | $17.0M | +25.3% |
| FY2017 | $13.5M | +35.2% |
| FY2016 | $10.0M | +62.0% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026